YPOGLYCEMIA stimulates rapid increases in the secretion of several hormones, including catecholamines, glucagon, cortisol, and growth hormone, that act in concert to increase the plasma glucose concentration. The chief role of the central nervous system in triggering the release of such counterregulatory hormones during hypoglycemia is well recognized. The specific region of the hypothalamus responsible for this process is probably the ventromedial region, because bilateral lesions or perfusion of D -glucose into this region reduces the increases in plasma glucagon and catecholamines in response to hypoglycemia in rats. 1,2 We describe a patient with a hypothalamic sarcoid infiltrate who had complete loss of the counterregulatory response to hypoglycemia.
CASE REPORTA 31-year-old woman in whom sarcoidosis had been diagnosed at the age of 27 years had an 18-month history of secondary amenorrhea, a 12-month history of weight gain of about 20 kg, and polydipsia and polyuria. Apart from the presence of obesity (weight, 86 kg; height, 171 cm) and a tendency toward hypothermia, the results of the physical examination were normal. A waterdeprivation test confirmed the diagnosis of central diabetes insipidus. Measurements of plasma and urinary hormones disclosed partial pituitary insufficiency, with low plasma concentrations of free thyroxine and cortisol and hyperprolactinemia. Plasma luteinizing hormone and follicle-stimulating hormone concentrations were normal, but the responses to gonadotropin-releasing hormone were supranormal. Magnetic resonance imaging revealed a normal pituitary gland but multiple infiltrates in the brain, including one in the hypothalamic region. The diagnosis of sarcoidosis was confirmed by the findings of a high plasma angiotensin-converting enzyme concentration, bilateral hilar lymphadenopathy with reticular interstitial infiltrates on computed tomography of the chest, and typical findings on transbronchial biopsy. Treatment was initiated with 32 mg of methylprednisolone per day, 100 µg of levothyroxine per day, 30 µg of desmopressin acetate per day, and a combination of 30 µg of ethinyl es-H tradiol and 75 µg of gestodene given on days 1 to 21 of the menstrual cycle. After one month of methylprednisolone therapy, pituitary magnetic resonance imaging showed complete resolution of all the infiltrates except the one in the hypothalamus, and it remained unchanged thereafter.During the next two years, the dose of methylprednisolone was gradually reduced to 6 mg per day and then replaced by cortisone acetate (37.5 mg per day). Shortly thereafter, the patient began to report episodes of faintness that lasted one to two hours and occurred about once a week. These episodes were unrelated to eating or activity and were not accompanied by other symptoms. The patient's only other symptoms were frequent episodes of hypernatremia resulting from impaired thirst perception, the development of cushingoid features, and progressive weight loss of 18 kg. She was hospitalized for assessment of faintness. On ad...